Your browser is no longer supported. Please, upgrade your browser.
IMV IMV Inc. daily Stock Chart
IMV Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own16.50% Shs Outstand45.00M Perf Week-7.44%
Market Cap151.20M Forward P/E- EPS next Y- Insider Trans- Shs Float42.82M Perf Month-17.04%
Income- PEG- EPS next Q- Inst Own19.50% Short Float0.14% Perf Quarter-42.47%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.87 Perf Half Y-33.60%
Book/sh0.19 P/B18.06 EPS next Y- ROA- Target Price- Perf Year-31.35%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.90 - 7.21 Perf YTD-35.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.40% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low15.86% ATR0.26
Employees51 Current Ratio- Sales Q/Q0.00% Oper. Margin- RSI (14)38.22 Volatility11.92% 6.37%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close3.56
ShortableNo LT Debt/Eq- EarningsMar 22 BMO Payout- Avg Volume32.75K Price3.36
Recom- SMA20-10.68% SMA50-21.44% SMA200-34.10% Volume14,090 Change-5.62%
Mar-25-19Initiated H.C. Wainwright Buy $11.50
Apr-18-19 07:05AM  IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors Business Wire -5.62%
Apr-16-19 09:31AM  IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update Business Wire +16.51%
Apr-04-19 07:05AM  IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference Business Wire
Apr-03-19 08:00AM  New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMVs Immunotherapy Program Business Wire
Mar-26-19 07:05AM  Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivacs Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer Business Wire
Mar-25-19 07:05AM  IMV Inc. to Present at Two Upcoming Investor Conferences Business Wire
Mar-21-19 05:05PM  IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs Business Wire
Mar-18-19 07:05AM  IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMVs DPX Technology Business Wire
Mar-12-19 07:05AM  IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019 Business Wire
Mar-11-19 08:41AM  IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares Business Wire
Mar-08-19 07:05AM  IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019 Business Wire
Mar-07-19 07:05AM  IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire
Mar-06-19 09:15AM  IMV Inc. Closes Previously Announced Public Offering Business Wire
Mar-01-19 10:02AM  IMV Inc. Announces Pricing of Public Offering GlobeNewswire -19.69%
Feb-28-19 04:51PM  IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares GlobeNewswire +6.88%
Jan-29-19 07:05AM  IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA GlobeNewswire
Jan-28-19 04:35PM  IMV to Present at 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-17-19 07:05AM  First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMVs DPX Delivery Platform in Ovarian Cancer Patients GlobeNewswire
Dec-13-18 04:05AM  IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress GlobeNewswire +6.20%
Dec-10-18 07:05AM  IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivacs Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018 GlobeNewswire
Dec-05-18 07:05AM  IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications GlobeNewswire
Nov-26-18 04:35PM  IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018 GlobeNewswire
Nov-20-18 07:05AM  IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer GlobeNewswire
Nov-16-18 08:10AM  Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-15-18 07:05AM  IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-06-18 07:05AM  Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors GlobeNewswire
Nov-02-18 07:05AM  IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details GlobeNewswire
Oct-23-18 07:05AM  IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018 GlobeNewswire
Oct-09-18 07:05AM  IMV Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Sep-27-18 07:05AM  IMV Provides Update on Progress of its DPX-RSV Program GlobeNewswire -5.16%
Sep-18-18 07:05AM  IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Mercks Keytruda® in Patients with DLBCL GlobeNewswire
Sep-11-18 07:05AM  IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications GlobeNewswire
Sep-04-18 05:50PM  IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia GlobeNewswire
Aug-23-18 07:05AM  IMV Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-09-18 07:05AM  IMV Inc. Reaches Multiple Milestones in Advanced Ovarian Cancer Clinical Trial GlobeNewswire +5.98%
Aug-08-18 07:05AM  IMV Inc. Announces Q2 2018 Financial Results GlobeNewswire -5.00%
Jul-31-18 07:05AM  IMV Inc. to Announce Second Quarter 2018 Financial Results and Host Earnings Call on August 8, 2018 GlobeNewswire
Jul-25-18 07:05AM  IMV Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jun-07-18 07:05AM  IMV Inc. Appoints Julia P. Gregory to Board of Directors GlobeNewswire
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Dartmouth, Canada.